Please assess the completion status of the following clinical trial:

Trial Title: Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ST-elevation myocardial infarction subject to acute PCI or non-ST elevation myocardial infarction subject to PCI within 72 hours after start of chest pain and:~* Revascularization by PCI,~* Signs of decreased wall-motion in at least 3 of 16 segments of the left ventricle~* Dyspnoea at rest and one of the following:~pulmonary edema, pulmonary congestion,need for CPAP or ventilator, need for IC diuretics or oliguria.~Subgroup of patients in cardiogenic shock: Systolic BP below 90 after 1 hour of volume therapy.~Exclusion Criteria:~* Age below 20 years~* Heart rate above 120 bpm~* Septic shock~* ARDS~* Creatinine \>450 micromol/l~* Hepatic impairment~* Significant mechanical outlet obstruction~* Allergy against study drug medication~* Anaemia (Hb \<8 g/dl)~* Pregnancy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): levosimendan
- 2 (Type: PLACEBO_COMPARATOR): Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).